Who are Limethason's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Dexamethasone Sodium Phosphate, Decadron, Emflaza, Fluocinolone Acetonide, Arnuity Ellipta, Lotemax.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dexamethasone-palmitate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Limethason — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Limethason (dexamethasone palmitate) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Corticosteroid. Area: Immunology.

unknown Corticosteroid Androgen receptor, Glucocorticoid receptor, Mineralocorticoid receptor Immunology Live · refreshed every 30 min

Target snapshot

Limethason (dexamethasone palmitate). Limethason works by binding to the glucocorticoid receptor, activating it and triggering a cascade of downstream effects that reduce inflammation and immune response.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Limethason TARGET	dexamethasone palmitate		unknown	Corticosteroid	Androgen receptor, Glucocorticoid receptor, Mineralocorticoid receptor
Dexamethasone Sodium Phosphate	dexamethasone phosphate	Merck & Co.	marketed	Corticosteroid	Androgen receptor, Glucocorticoid receptor, Mineralocorticoid receptor	1959-01-01
Decadron	Decadron	University of Miami	marketed		Androgen receptor, Glucocorticoid receptor, Mineralocorticoid receptor
Emflaza	DEFLAZACORT	Ptc Therap	marketed	Corticosteroid [EPC]		2017-01-01
Fluocinolone Acetonide	FLUOCINOLONE	Eurofarma	marketed	Corticosteroid [EPC]		2016-01-01
Arnuity Ellipta	FLUTICASONE FUROATE	Haleon Us Holdings	marketed	Corticosteroid	Glucocorticoid receptor	2007-01-01
Lotemax	LOTEPREDNOL ETABONATE	Bausch Health	marketed	Corticosteroid	Glucocorticoid receptor	1998-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2030-02-12 — Dexamethasone Sodium Phosphate · 8563027 · Method of Use · US
2030-05-14 — Dexamethasone Sodium Phosphate · 8409606 · Formulation · US
2032-05-11 — Dexamethasone Sodium Phosphate · 10799642 · Formulation · US
2033-05-03 — Lotemax · 11219596 · Method of Use · US
2033-05-03 — Lotemax · 11219597 · Method of Use · US
2033-05-03 — Lotemax · 11596599 · Method of Use · US
2033-05-03 — Lotemax · 10857096 · Method of Use · US
2033-05-03 — Lotemax · 10864219 · Method of Use · US
2033-05-03 — Lotemax · 10945948 · Method of Use · US
2033-05-03 — Lotemax · 10940108 · Method of Use · US
2033-05-03 — Lotemax · 9737491 · Method of Use · US
2033-05-03 — Lotemax · 9827191 · Formulation · US
2033-05-03 — Lotemax · 10993908 · Method of Use · US
2033-05-03 — Lotemax · 12115246 · Formulation · US
2033-05-03 — Lotemax · 10688045 · Formulation · US
2033-05-03 — Lotemax · 11642317 · Formulation · US
2033-05-03 — Lotemax · 10646437 · Formulation · US
2033-05-03 — Lotemax · 9393213 · Formulation · US
2033-05-03 — Lotemax · 10646436 · Formulation · US
2033-05-03 — Lotemax · 11872318 · Formulation · US
2033-05-03 — Lotemax · 9056057 · Formulation · US
2033-05-03 — Lotemax · 9532955 · Method of Use · US
2033-05-03 — Lotemax · 10058511 · Formulation · US
2034-05-23 — Dexamethasone Sodium Phosphate · 10159683 · Formulation · US
2034-05-23 — Dexamethasone Sodium Phosphate · 10028965 · Method of Use · US
2034-06-22 — Dexamethasone Sodium Phosphate · 10022502 · Method of Use · US
2036-01-26 — Lotemax · 11534395 · Formulation · US
2036-10-07 — Dexamethasone Sodium Phosphate · 12150896 · Method of Use · US
2036-12-23 — Lotemax · 10596107 · Formulation · US
2037-11-16 — Dexamethasone Sodium Phosphate · 11458041 · Method of Use · US

Sponsor landscape (Corticosteroid class)

· 22 drugs in this class
Pfizer · 9 drugs in this class
Chiesi Farmaceutici S.p.A. · 6 drugs in this class
Assistance Publique - Hôpitaux de Paris · 6 drugs in this class
Merck & Co. · 5 drugs in this class
LEO Pharma · 4 drugs in this class
Allergan · 4 drugs in this class
AbbVie · 4 drugs in this class
Bristol-Myers Squibb · 3 drugs in this class
Bausch Health · 3 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Limethason — Competitive Intelligence Brief. https://druglandscape.com/ci/dexamethasone-palmitate. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing